| Influvac, Injektionssuspension - Fertigspritze(n) à 0.5 ml | | 00485009 | | Mylan Pharma GmbH | | Influvac, Injektionssuspension | | 24.06.1988 | | | | | 30.07.2014 | | Influenza, Inactivated, Split Virus Or Surface Antigen (J07BB02) | | | | WHO-DDD | | 30.06.2022 | | 08.08. | | Fertigspritze(n) à 0.5 ml | | 08.08. | | | | B | | | | Yes | | | | IP | | | | 9.10 | | Yes | | | | | | | | | k.A. | | 18.65 | | FB | | | | 7680004850097 | | Impfstoffe | | 5893698 | | |
| | Composition | | haemagglutininum influenzae A (H1N1) (Virus-Stamm A/California/7/2009 (H1N1)-like: reassortant virus NYMC X-181) 15 µg, haemagglutininum influenzae A (H3N2) (Virus-Stamm A/Texas/50/2012 (H3N2)-like: reassortant virus NYMC X-223A) 15 µg, haemagglutininum influenzae B (Virus-Stamm B/Massachusetts/2/2012-like: reassortant virus NYMC BX-51B) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, residui: ovalbuminum max. 0.1 µg, formaldehydum et cetrimidum et polysorbatum 80 et gentamicinum nihil, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml. | | Packungsbestandteile | | Injection suspension | | | | | | Active Agent | Dose |
|---|
| Haemagglutininum Influenzae a (H1N1) (Virus-Stamm A/california/7/2009 (H1N1)-Like: Reassortant Virus nymc X-181) | 15 µg | | Haemagglutininum Influenzae a (H3N2) (Virus-Stamm A/texas/50/2012 (H3N2)-Like: Reassortant Virus nymc X-223a) | 15 µg | | Haemagglutininum Influenzae b (Virus-Stamm B/massachusetts/2/2012-Like: Reassortant Virus nymc Bx-51B) | 15 µg |
|
| | Source | | Data was imported : 02.09.2015
Swissmedic Registration : 00485
Sequence : 27
Product name : Influvac, Injektionssuspension
Registration owner: : BGP Products GmbH
Product group :
Index Therapeuticus (BSV) : 08.08.
Medication Code : Impfstoffe
Date of registration : 24.06.1988
Valid until : 30.06.2017
Package number : 009
Show package size : 1 x 0.5 ml
Commercial Form/Unit : Fertigspritze(n)
Swissmedic categorie. : B
Active Agents : haemagglutininum influenzae A (H1N1) (Virus-Stamm A/California/7/2009 (H1N1)-like: reassortant virus NYMC X-181), haemagglutininum influenzae A (H3N2) (Virus-Stamm A/Texas/50/2012 (H3N2)-like: reassortant virus NYMC X-223A), haemagglutininum influenzae B (Virus-Stamm B/Massachusetts/2/2012-like: reassortant virus NYMC BX-51B)
Composition : haemagglutininum influenzae A (H1N1) (Virus-Stamm A/California/7/2009 (H1N1)-like: reassortant virus NYMC X-181) 15 µg, haemagglutininum influenzae A (H3N2) (Virus-Stamm A/Texas/50/2012 (H3N2)-like: reassortant virus NYMC X-223A) 15 µg, haemagglutininum influenzae B (Virus-Stamm B/Massachusetts/2/2012-like: reassortant virus NYMC BX-51B) 15 µg, kalii chloridum, kalii dihydrogenophosphas, dinatrii phosphas dihydricus, natrii chloridum, calcii chloridum dihydricum, magnesii chloridum hexahydricum, residui: ovalbuminum max. 0.1 µg, formaldehydum et cetrimidum et polysorbatum 80 et gentamicinum nihil, aqua ad iniectabilia q.s. ad suspensionem pro 0.5 ml.
| |
|
|
